Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
LAV Biosciences Fund V, L.P. - 30 Sep 2026 SCHEDULE 13G Report for ADARx Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (ADRX)
- Filing manager
- LAV Biosciences Fund V, L.P.
- Reporting owner
- Yi Shi
- Beneficially owned shares
- 11,858,655 shares
- Large-stake signal
-
Ownership
11%Beneficial ownership of this reported class.
Shares
11,858,655 sharesShares beneficially owned as disclosed.
Event date
30 Sep 2026Date tied to the ownership event or amendment.
Accepted by SEC
16 Oct 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 11%
- Symbol
- ADRX
- Shares outstanding
- 106,834,730 shares
- SEC form
- SCHEDULE 13G
- Accepted by SEC
- 16 Oct 2026, 16:18:15 UTC
- Event date
- 30 Sep 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Filing notes and source
Key filing fact
LAV Biosciences Fund V, L.P. disclosed 11% ownership in ADARx Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (ADRX) on 30 Sep 2026.
Key facts
- LAV Biosciences Fund V, L.P. filed SCHEDULE 13G for ADARx Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (ADRX).
- Disclosed ownership: 11%.
- Date of event: 30 Sep 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 16 Oct 2026, 16:18.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (4)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| LAV Biosciences Fund V, L.P. | 10% | 11,243,179 | 0 | 11,243,179 | /s/ Yi Shi | Yi Shi/Managing Partner of LAV Corporate V GP, Ltd., the General Partner of LAV GP V, L.P., its General Partner | |
| LAV Fund VI, L.P. | 0.3% | 307,738 | 0 | 307,738 | /s/ Yi Shi | Yi Shi/Managing Partner of LAV Corporate VI GP, Ltd., the General Partner of LAV GP VI, L.P., its General Partner | |
| LAV Fund VI Opportunities, L.P. | 0.3% | 307,738 | 0 | 307,738 | /s/ Yi Shi | Yi Shi/Managing Partner of LAV Corporate VI GP Opportunities, Ltd., the General Partner of LAV GP VI Opportunities, L.P., its General Partner | |
| Yi Shi | 11% | 11,858,655 | 0 | 11,858,655 | /s/ Yi Shi | Yi Shi/an Individual |
CIK / CUSIP context first